J. P. Stewart

This study shows that a recombinant SARS-CoV-2 virus lacking ORF10 start and internal methionine codons is attenuated in hamsters, with reduced lower respiratory tract viral titre and increased reversion to wild-type.

This paper investigates probenecid's antiviral activity against SARS-CoV-2 in Vero E6 cells and Syrian golden hamsters, finding no significant inhibition of viral replication or cytopathic effects.

This study compares the severity of SARS-CoV-2 Omicron-B.1.1.529, Pango B, and Delta variants in a mouse model, finding Omicron causes less severe disease with lower viral load and inflammation.

This paper demonstrates that a multimerised SARS-CoV-2 RBD vaccine using a stable scaffold provides enhanced antibody responses and complete protection in mice.

This study shows that SARS-CoV-2 ORF8 protein modulates cytokine expression in human macrophages, with sequence polymorphisms affecting IL-6 and IL-8 secretion.

This study evaluates intranasal nafamostat and camostat for preventing SARS-CoV-2 infection in Syrian golden hamsters, finding nafamostat effective in keeping viral RNA undetectable for 7 days.

This study investigates SARS-CoV-2 variant neuroinvasion in K18-hACE2 mice, finding CNS spread in all variants except Omicron, with microglial activation and immune cell apoptosis observed.

The paper analyzes SARS-CoV-2 sequence variation in patient samples and compares the in vitro growth of B.1.1.7 and B.1.351 variants to other isolates, finding no significant difference in growth for B.1.1.7.

This study shows that prior SARS-CoV-2 infection in Syrian Golden Hamsters protects against re-exposure to variants B.1.1.7 and B.1.351, suggesting immunity may limit disease from emerging variants.

The paper identifies and quantifies SARS-CoV-2 leader-TRS-junctions in samples, showing phasic sgmRNA transcription in animal models and dysregulation in humans.

This study shows that sequential infection with influenza A virus followed by SARS-CoV-2 in mice leads to more severe disease and encephalitis compared to single infections.

This paper shows that pixatimod inhibits SARS-CoV-2 by disrupting the Spike-ACE2 interaction, demonstrating its potential as an anti-COVID-19 therapeutic.

This study shows that non-canonical autophagy, mediated by the WD and linker domains of ATG16L1, protects against lethal influenza A virus infection by limiting viral replication and inflammation in airway epithelial cells.

This study identifies TRIM22 as a constitutively expressed antiviral factor in the respiratory tract that restricts influenza A virus infection independently of cytokine-mediated immunity.